Stocks Health care INKT

NASDAQ · Health care

MiNK Therapeutics, Inc. (INKT)

It posted a net loss of $11.4M. At June 30, 2026 it held $8.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Watch INKT in 60 seconds

Follow INKT

Free, no password. An email when INKT files with the SEC.

Key facts about MiNK Therapeutics, Inc.

Net worth

MiNK Therapeutics, Inc. has a market value (market cap) of $52.5M at the latest share price, and shareholders' equity of -$14M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Cash flow

In fiscal 2025 operations used $5.9M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

MiNK Therapeutics, Inc.'s next report is expected around December 7, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What MiNK Therapeutics, Inc. does

MiNK Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INKT.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What MiNK Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 13, 2026
   Employee stock plan registration S-8
2. August 13, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.62 versus -$1.06.
3. August 13, 2026
   Quarterly results 8-K
4. June 23, 2026
   Shareholder vote results 8-K
5. May 15, 2026
   Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.57 versus -$0.70.
6. May 15, 2026
   Quarterly results 8-K
7. April 30, 2026
   Annual report to shareholders ARS
8. April 30, 2026
   Proxy statement DEF 14A
9. March 31, 2026
   Annual report 10-K · period to December 31, 2025Diluted EPS -$2.93 versus -$2.86.
10. March 31, 2026
    Quarterly results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 2, 2026. Insider transactions on SEC

Insider trades

What the people running MiNK Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns INKT

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

7 insiders reported holding 208,453 shares in total, about $2.1M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about INKT

What does MiNK Therapeutics, Inc. do?

MiNK Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as INKT. Its shares trade on NASDAQ under the ticker INKT.

What is MiNK Therapeutics, Inc.'s net worth?

MiNK Therapeutics, Inc. has a market value (market cap) of $52.5M at the latest share price, and shareholders' equity of -$14M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is MiNK Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $11.4M.

When did MiNK Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 2, 2026.

When is MiNK Therapeutics, Inc.'s next earnings report?

MiNK Therapeutics, Inc.'s next report is expected around December 7, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Compare INKT with

Compare INKT with any company

Follow INKT

Get an email when MiNK Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow INKT

Free, no password. An email when INKT files with the SEC.

Where the numbers come from

Financial figures are the values MiNK Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.